LRRC49 Inhibitors
LRRC49 inhibitors belong to a chemical class that targets LRRC49, a protein implicated in various cellular processes. LRRC49, short for Leucine-Rich Repeat-Containing 49, is a protein characterized by the presence of leucine-rich repeats (LRRs), which are structural motifs commonly found in proteins involved in protein-protein interactions. These inhibitors are designed to modulate the activity of LRRC49, and their development stems from the understanding of LRRC49's role in specific cellular functions.
The leucine-rich repeats in LRRC49 suggest its involvement in mediating protein-protein interactions, possibly within signaling cascades or cellular recognition processes. Inhibitors targeting LRRC49 aim to interfere with these interactions, thereby influencing downstream cellular events. The design and development of LRRC49 inhibitors often involve structural studies to identify key binding sites and molecular interactions. Understanding the chemical structure and properties of LRRC49 inhibitors is crucial for optimizing their efficacy and specificity. Ongoing research in this field focuses on elucidating the precise mechanisms by which LRRC49 inhibitors exert their effects and exploring potential applications in various cellular contexts. As the understanding of LRRC49 and its inhibitors advances, this chemical class holds promise for contributing to our knowledge of fundamental cellular processes and may have implications for future research in diverse scientific disciplines.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK, which is upstream of ERK in the MAPK/ERK pathway. By inhibiting MEK, U0126 prevents the activation of ERK, which could lead to decreased activity of LRRC49 if LRRC49 is regulated by ERK signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, a key enzyme in the PI3K/Akt pathway. Inhibition of PI3K leads to reduced Akt phosphorylation, which could result in lower activity of LRRC49 if LRRC49's function is influenced by Akt-mediated signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mTOR pathway by binding to mTORC1. This leads to a decrease in protein synthesis and cell proliferation, potentially affecting LRRC49 if its function is linked to mTOR signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, the compound may reduce the activity of LRRC49 if it is involved in pathways that are regulated by p38 MAPK activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK1, which also impacts the MAPK/ERK pathway. By blocking MEK1, PD98059 could reduce LRRC49 activity if LRRC49 is regulated by MEK1-dependent signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a covalent inhibitor of PI3K, leading to a decrease in Akt signaling. If LRRC49 activity is PI3K/Akt-dependent, its functional activity would be indirectly decreased by Wortmannin. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK, a kinase downstream of the small GTPase Rho. Inhibition of ROCK could affect the cytoskeletal organization and potentially decrease LRRC49 activity if it is associated with Rho/ROCK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is involved in the stress-activated MAPK pathway. By inhibiting JNK, SP600125 could lead to decreased LRRC49 activity if LRRC49 functions are responsive to JNK signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. If LRRC49 stability relies on proteasome activity, Bortezomib could indirectly decrease its functional activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR. If LRRC49 is modulated by any of these kinases, Imatinib could lead to a functional decrease in LRRC49. | ||||||